Compare HUBC & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUBC | LGVN |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 7.8M |
| IPO Year | 2022 | 2021 |
| Metric | HUBC | LGVN |
|---|---|---|
| Price | $0.22 | $1.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.25 |
| AVG Volume (30 Days) | ★ 931.2K | 69.7K |
| Earning Date | 11-11-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | N/A | $46.15 |
| Revenue Next Year | N/A | $396.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.06 | $0.48 |
| 52 Week High | $8.68 | $7.60 |
| Indicator | HUBC | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 35.92 | 33.00 |
| Support Level | $0.11 | $0.61 |
| Resistance Level | $0.31 | $7.30 |
| Average True Range (ATR) | 0.12 | 0.22 |
| MACD | -0.07 | -0.05 |
| Stochastic Oscillator | 1.63 | 16.28 |
Hub Cyber Security Ltd is engaged in developing reliable quality assurance systems that support process and product enhancement and also operates in the industry of secured data fabric. The company serves various organizations and institutions operating in the security, electronics, aviation, telecommunications, and banking. The company has two operating segments: Product and Technology Segment and Professional Services Segment. The majority of revenue comes from the professional services segment, which provides data and cybersecurity and system security and reliability solutions and related services such as consulting, planning, integrating and ongoing servicing of cybersecurity, risk management, reliability and security projects and fully managed corporate cybersecurity services.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.